RATIONALE-306研究(NCT03783442)是一项具有里程碑意义的研究,研究旨在评估替雷利珠单抗联合化疗对比安慰剂联合化疗作为ESCC一线治疗的疗效和安全性。研究结果显示,替雷利珠单抗联合化疗的中位总生存期(OS)达17.2个月、无进展生存期(PFS)达7.3...
) + CT demonstrated significant overall survival (OS) benefit vs PBO + CT as first-line (1L) therapy for advanced ESCC in all randomized patients (pts; stratified HR 0.66) and pts with PD-L1 Tumor Area Positivity (TAP) score ≥10% (stratified HR 0.62) (RATIONALE-306; NCT03783442). ...